Skip to main content

Drug Interactions between asciminib and epirubicin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

epiRUBicin asciminib

Applies to: epirubicin and asciminib

MONITOR: Coadministration with asciminib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. In vitro, asciminib is a substrate and inhibitor of P-gp, an efflux transporter expressed in the gastrointestinal tract, liver, and kidney. However, drug interaction studies with P-gp substrates have not been conducted.

MANAGEMENT: Caution is advised when asciminib is used concomitantly with drugs that are substrates of P-gp, particularly sensitive substrates or those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever asciminib is added to or withdrawn from therapy. The prescribing information recommends closely monitoring for the development of adverse reactions in patients receiving asciminib therapy with certain P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. In addition, the prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a P-gp inhibitor like asciminib and for any dosage adjustments that may be required.

References

  1. (2021) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

Moderate

asciminib food

Applies to: asciminib

ADJUST DOSING INTERVAL: Food may reduce the oral bioavailability of asciminib. When a single 40 mg dose of asciminib was administered with a low-fat meal (400 calories; 25% fat) in healthy volunteers, asciminib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 35% and 30%, respectively, compared to asciminib administered in the fasted state. Administration with a high-fat meal (1000 calories; 50% fat) decreased the Cmax and AUC of asciminib by 68% and 62%, respectively.

MANAGEMENT: To ensure adequate asciminib exposures, food consumption should be avoided for at least 2 hours before and 1 hour after taking asciminib.

References

  1. (2021) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals
  2. (2022) "Product Information. Scemblix (asciminib)." Novartis Pharmaceuticals UK Ltd, Scemblix 20 mg film-

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer